The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

doi:10.1158/2159-8290.CD-13-0617

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

Cancer discovery - 1 Jan 2014

Van Allen Eliezer M, Wagle Nikhil, Sucker Antje, Treacy Daniel J, Johannessen Cory M, Goetz Eva M, Place Chelsea S, Taylor-Weiner Amaro, Whittaker Steven, Kryukov Gregory V, Hodis Eran, Rosenberg Mara, McKenna Aaron, Cibulskis Kristian, Farlow Deborah, Zimmer Lisa, Hillen Uwe, Gutzmer Ralf, Goldinger Simone M, Ugurel Selma, Gogas Helen J, Egberts Friederike, Berking Carola, Trefzer Uwe, Loquai Carmen, Weide Benjamin, Hassel Jessica C, Gabriel Stacey B, Carter Scott L, Getz Gad, Garraway Levi A, Schadendorf Dirk

Abstract excerpt

Most patients with BRAF(V600)-mutant metastatic melanoma develop resistance to selective RAF kinase inhibitors. The spectrum of clinical genetic resistance mechanisms to RAF inhibitors and options for salvage therapy are incompletely understood. We performed whole-exome sequencing on formalin-fixed, paraffin-embedded tumors from 45 patients with BRAF(V600)-mutant metastatic melanoma who received vemurafenib or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Indoles

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Oximes

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 24265153
DOI: 10.1158/2159-8290.CD-13-0617
PMCID: PMC3947264

Genes

BRAF
MITF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.PMID 24265153Read ↗

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.Semantic proximity Read ↗

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Semantic proximity Read ↗

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity Read ↗

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.Semantic proximity Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression.Semantic proximity Read ↗

Emerging insights into resistance to BRAF inhibitors in melanoma.Semantic proximity Read ↗

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.Semantic proximity Read ↗

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapySemantic proximity Read ↗

Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.Semantic proximity Read ↗

C-RAF mutations confer resistance to RAF inhibitors.Semantic proximity Read ↗

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.